Less Ads, More Data, More Tools Register for FREE

Pin to quick pickshVIVO Regulatory News (HVO)

Share Price Information for hVIVO (HVO)

Share Price is delayed by 15 minutes
Get Live Data
8.40    0.05 (0.60%)
Bid:
8.30
Ask:
8.50
Spread: 0.20 (2.41%)
Market Cap: £57.83m
HVO Live PriceLast checked at - London Stock Exchange

Intraday hVIVO Share Chart

Offer Wholly Unconditional

17 Jan 2020 07:00

RNS Number : 0961A
Open Orphan PLC
17 January 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF ANY SUCH JURISDICTION

 

17 January 2020

Recommended All Equity Offer

for

HVIVO PLC ("HVIVO")

to merge with

OPEN ORPHAN PLC ("OPEN ORPHAN")

 

 Offer Wholly Unconditional

Introduction

On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and to be issued share capital of hVIVO (the "Offer"). Under the terms of the Offer, hVIVO Shareholders will be entitled to receive 2.47 New Open Orphan Shares for every one hVIVO Share. The Offer represents a value of approximately 15.56 pence per hVIVO Share and a premium of 33.8 per cent. based upon the hVIVO Closing Price on 6 December 2019, being the last practicable date prior to announcement of the Offer, valuing hVIVO at approximately £12.96 million.

On 31 December 2019, Open Orphan announced that the Offer had been declared unconditional as to acceptances and on 14 January 2020 announced that it had received acceptances in respect of 77,348,100 hVIVO Shares, representing approximately 92.5 per cent. of the issued ordinary share capital of hVIVO.

Offer Wholly Unconditional

Open Orphan announces that it has decided, in accordance with the Offer Document, to waive the outstanding conditions under the Offer. Accordingly, there are no further conditions to be satisfied and the Offer is now unconditional in all respects.

Admission of the Enlarged Share Capital

Application has been made for the admission of the Consideration Shares and the Existing Ordinary Shares, being 445,622,374 Ordinary Shares to trading on AIM and Euronext Growth, which is expected to become effective and dealings commence at 8.00 a.m. on 20 January 2020.

Compulsory acquisition

Open Orphan intends to shortly exercise its rights pursuant to the provisions of sections 974-991 of the Companies Act to compulsorily acquire the remaining hVIVO Shares. The compulsory acquisition will be settled on the same terms as the Offer and hVIVO Shareholders will be entitled to receive 2.47 Open Orphan Shares for every 1 hVIVO Share.

In exercising such rights in respect of hVIVO Shares held by hVIVO Shareholders in, or with a registered address in, a Restricted Jurisdiction, Open Orphan may elect to arrange for such hVIVO Shares to be sold on behalf of the relevant hVIVO Shareholder and the proceeds (less the costs and expenses of such sale) remitted to such hVIVO Shareholder.

Enquiries:

 

Open Orphan plc

Cathal Friel, Chief Executive Officer

 

+353 (0)1 644 0007

Arden Partners plc (Nominated Adviser and Joint Broker)

John Llewellyn-Lloyd / Ben Cryer

 

+44 (0)20 7614 5900

JE Davy (Euronext Adviser and Joint Broker)

Anthony Farrell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
OUPUNUARRRUAAUR
Date   Source Headline
1st Jun 202612:00 pmRNS-RConsultancy contract with Decoy Therapeutics
29th May 20267:00 amRNSGrant of awards under Long Term Incentive Plan
20th May 20267:00 amRNSCapital Markets Day
13th May 20261:40 pmRNSResult of AGM
12th May 20269:45 amRNSHolding(s) in Company
7th May 20267:00 amRNS£6m Influenza HCT contract signed
24th Apr 20266:14 pmRNSDirector/PDMR Shareholding
22nd Apr 20267:00 amRNSHCT contract signed with ILiAD Biotechnologies
17th Apr 20267:00 amRNSAnnual Report & Notice of AGM
15th Apr 20267:00 amRNSFinal Results 2025
14th Apr 20267:01 amRNS-RhVIVO launches unified brand identity
14th Apr 20267:00 amRNSInfluenza HCT contract signed with Traws Pharma
7th Apr 20267:00 amRNSNotice of Results
26th Mar 20265:19 pmRNSHolding(s) in Company
27th Feb 20263:31 pmRNSHolding(s) in Company
23rd Feb 20267:00 amRNSIssue of Equity and Total Voting Rights
16th Feb 20263:05 pmRNSHolding(s) in Company
11th Feb 20263:11 pmRNSHolding(s) in Company
29th Jan 20267:00 amRNSTrading Update
27th Jan 20267:00 amRNSNotice of Trading Update
18th Dec 20257:00 amRNSAppointment of Non-Executive Director
15th Dec 20252:47 pmRNSCEO & CFO Share Purchase
27th Nov 20257:00 amRNS-RMSD to acquire Cidara
20th Nov 20257:00 amRNS>£5 million CRS contracts signed
11th Nov 20257:00 amRNS-RPositive data from novel human challenge models
6th Nov 20255:05 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNS-RPresentation at Jefferies Healthcare Conference
27th Oct 20253:01 pmRNSHolding(s) in Company
23rd Sep 20257:00 amRNSInterim results
4th Sep 20257:00 amRNSNotice of Results
1st Sep 20257:00 amRNSAppointment of Non-Executive Chair
29th Jul 20257:00 amRNSProposed appointment of Chair
22nd Jul 20257:00 amRNSH1 Trading update
18th Jul 20257:00 amRNSDirectorate Change
9th Jul 20257:00 amRNSNotice of Trading Update
1st Jul 20254:04 pmRNSHolding(s) in Company
30th Jun 20257:00 amRNS-RPositive results from client Phase 2b field study
5th Jun 20251:00 pmRNSResult of AGM
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSTrading update
29th May 20257:00 amRNSAppointment of Independent Non-Executive Director
12th May 20257:00 amRNSAnnual Report, Notice of AGM & Directorate Change
10th Apr 20257:05 amRNSExercise of Options
10th Apr 20257:00 amRNSFinal results
26th Mar 20251:51 pmRNSAIM Rule 17 and Schedule 2(g) Update
21st Mar 20257:00 amRNSNotice of Results
7th Mar 20257:00 amRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSAcquisition of Cryostore for up to £3.2m
17th Feb 20257:00 amRNS£2m hMPV characterisation study contract
5th Feb 20257:00 amRNS-RShionogi reports positive RSV trial results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.